Skip to main content
In stock | Targeted Therapy (Antibody)

Brolucizumab (Onc Adjacent)

Oncology Type Solid Tumour
Drug Class / Mechanism Anti-VEGF / VEGFR Agent
No Image
Description

Brolucizumab (Onc Adjacent) is classified as an Anti-VEGF / VEGFR Agent, sourced for use within our Targeted Therapy (Antibody) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy (Antibody)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3